Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8176 to 8190 of 8942 results

  1. Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]

    In development Reference number: GID-TA11607 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]

    In development Reference number: GID-TA11157 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Avelumab for previously treated platinum-resistant ovarian cancer [ID1497]

    In development Reference number: GID-TA10404 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TSID10725]

    In development Reference number: GID-TA11014 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Dexmedetomidine for treating agitation associated with schizophrenia [TSID10726]

    In development Reference number: GID-TA11015 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development Reference number: GID-TA11402 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]

    Discontinued Reference number: GID-TA10228

    Technology appraisal guidance
    Discontinued

  8. Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135]

    Discontinued Reference number: GID-TA10233

    Technology appraisal guidance
    Discontinued

  9. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued Reference number: GID-TA10234

    Technology appraisal guidance
    Discontinued

  10. Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

    Discontinued Reference number: GID-TA10236

    Technology appraisal guidance
    Discontinued

  11. Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]

    Discontinued Reference number: GID-TA10242

    Technology appraisal guidance
    Discontinued

  12. Pembrolizumab for previously treated endometrial cancer [ID1205]

    Discontinued Reference number: GID-TA10243

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]

    Discontinued Reference number: GID-TA10244

    Technology appraisal guidance
    Discontinued

  14. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued Reference number: GID-TA10254

    Technology appraisal guidance
    Discontinued

  15. ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

    Discontinued Reference number: GID-TA10259

    Technology appraisal guidance
    Discontinued